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Introduction
It has been reported that upon binding to membrane
TNF (mTNF), adalimumab may activate the complement
system, leading to complement dependent cytotoxicity
(CDC) of targeted cells. CDC has been implicated in
mechanisms of action conferring adalimumab’s efficacy.
CDC has also been proposed to contribute to the reacti-
vation of opportunistic infections. CDC attributed to ada-
limumab in the U.S. product label refers to a mouse cell
line transfected with a non-cleavable form of human
TNF (SP2/0-11A5).
Aim
The objective of this preclinical study was to assess the
CDC activity of adalimumab in four different cell popu-
lations expressing human TNF: 1) mTNF-transduced
human MonoMax-6 (MM6); 2) LPS-activated human
acute monocytic leukemia cell line (THP-1); 3) LPS-
activated human peripheral blood mononuclear cells
(PBMC) from normal and Rheumatoid arthritis (RA)
donors; and 4) mTNF-expressing, murine myeloma
SP2/0-11A5. We also determined surface expression of
complement regulatory proteins and adalimumab bind-
ing on these cells.
Methods
Calcein-labeled cells were cultured with test antibodies
plus complement and released calcein from dying cells
was measured to assess CDC. Expression of mTNF and
complement regulatory protein expression was mea-
sured by flow cytometry.
Results
Adalimumab was not associated with CDC of mTNF-
MM6, LPS-activated THP-1, normal PBMC or RA PBMC.
As previously reported, adalimumab was associated with
CDC of human TNF transfected murine SP2/0-11A5-1
cells. Adalimumab was shown to bind to TNF expressed
on the surface of activated human PBMC or THP-1 cell
lines, and also to non-cleavable mutant forms of mTNF
expressed on human or mouse cell lines. Expression of
complement regulatory proteins was observed for all
human cells, but was absent from mTNF-transfected
mouse cell line, Sp2/0-11A5.
Conclusions
Adalimumab was not associated with CDC reactions
and the death of human cells from healthy volunteers or
RA patients nor human cells lines. The expression of
complement regulatory proteins by the human cells may
account for the difference from the data reported for
transfected murine SP2/0-11A5-1 cells.
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